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Melioidosis is a serious infection, which can involve multiple systems. We report a case of pulmonary
melioidosis with the initial presentation mimicking a partially treated pneumonia complicated by right-
sided pleural effusion. The patient is a 49-year old man who did not respond to parenteral ceftriaxone
and tazobactam/piperacillin therapy. However, upon culture and sensitivity results from blood and
pleural samples isolated Burkholderia pseudomallei; antimicrobial therapy was de-escalated to parenteral
ceftazidime. Within 72 h duration, his fever subsided and other respiratory symptoms improved
tremendously. This case highlights the importance of early recognition of B. pseudomallei in pulmonary
infection in order for prompt institution of appropriate antibiotics treatment; thus reducing morbidity
and mortality.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Melioidosis is a common infection in the tropical countries
including Malaysia. This infection is caused by environmental
saprophyte-Burkholderia pseudomallei. It is a gram-negative bac-
terium commonly transmitted via direct contact with infected soil
(i.e. gardening or swimming). Melioidosis can present acutely with
fever and chills secondary to a localized infection or septicemia.
Chronic cases are seen when abscesses developed insidiously at
various tissue sites or organs. Thus treatment for persistent infec-
tion can be challenging [1]. Diabetes is the commonest concurrent
condition identiﬁed; with a ﬁgure as high as 44% and 60% reported
in Thailand and Malaysia respectively [2,3].
1.1. Case presentation
A 49-year-old man, non-smoker presented to our center with
intermittent fever, productive cough with whitish sputum and
right-sided pleuritic chest pain for one week duration. Prior to
admission, he had received a course of oral antibiotic (erythro-
mycin) for ﬁve days. Unfortunately, his symptoms did not improve.oxazole.
), sopian301084@gmail.com
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Ltd. This is an open access article uHe has no past medical illness and works as a teacher. There was no
recent history of contact with soil (i.e. gardening/planting), swim-
ming in the river, traveling or jungle trekking. There were also no
constitutional symptoms such as loss of appetite or loss of weight.
1.2. Examination
His temperature was 38.4 C, heart rate was 100/min (regular
rhythm), respiratory rate 20 breaths/min, blood pressure 103/
59 mmHg, and his oxygen saturation was 96% on room air. Clini-
cally, there was a moderate right-sided pleural effusion as evidence
by a reduced in chest expansion, vocal resonance, tactile fremitus,
stony dullness on percussion and a reduced air entry on ausculta-
tion. Bronchial breath sounds were heard at the right mid-zone.
Otherwise, there were no lymphadenopathy or organomegaly
detected.
1.3. Investigations
Blood test showed white blood cells of 12.0  109/L; predomi-
nantly neutrophils, 70.2%; fasting blood sugar of 17 mmol/L and
glycated hemoglobin (HbAIC) level of 7.6%, erythrocyte sedimen-
tation rate of 97 mm/h; C-reactive protein, 24 mg/dL; serum so-
dium, 129 mmol/L; potassium, 4.3 mmol/L; urea, 5.7 mmol/L;
creatinine, 99umol/L and alanine aminotransferase (ALT), 72 U/L.
Culture and sensitivity performed on three sets of sputum did notnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Erect chest radiograph of the patient on initial presentation. Air-space hetero-
geneous opacities noted over the right lower zone accompany by a pleural effusion.
Fig. 2. Erect chest radiograph of the patient repeated after completion of treatment (1
month later).
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space opacities at the right lower zone and blunting of the right
costophrenic angle in keeping with infective process complicated
with pleural effusion.
Pleurocentesis yield straw colored pleural ﬂuid. Biochemical
results of the pleural ﬂuid were consistent with a complicated
parapneumonic effusion. Pleural ﬂuid lactate dehydrogenase
(LDH), 2460 U/L; glucose, 7.6 mmol/l; and pH, 7.0. Pleural ﬂuid
cytology revealed numerous small, reactive lymphocytes with
neutrophils and the presence of some red blood cells. Staining for
acid-fast bacilli (AFB) was negative. Subsequently pleural drainage
was carried out via an 8F pigtail catheter.
The patient was started on parenteral ceftriaxone and oral azi-
thromycin. This was replaced with parenteral tazobactam/piper-
acillin in view of poor clinical response and persistent fever for
more than 48 h. Subsequently, culture results of the pleural ﬂuid
and blood were reported positive for B. pseudomallei, which was
sensitive to ceftazidime. Treatment was deescalated to parenteral
ceftazidime 2 g 8hourly. Following this, the patient showed
tremendous improvement and he became afebrile three days after
initiation of ceftazidime. Further work-up revealed no occult ab-
scesses detected on the abdominal sonography. On the other hand,
the patient was also diagnosed to have type-2 diabetes mellitus. A
good glycemic control was achieved after initiation of insulin
therapy.
The patient was treated with two weeks duration of parenteral
Ceftazidime. Subsequent white cell counts and C-reactive protein
levels showed a reducing trend and measured 5.9  109/L and
5.83 mg/dL respectively upon discharge. The pigtail drainage
catheter was removed on day six after drainage amount of less than
50 cc per day for two consecutive days. The total drainage was
1650 cc. Following this, the patient was given outpatient treatment
with oral Doxycycline 100 mg 12 hourly and three tablets of
trimethoprim/sulphamethoxazole 80/400 mg (TMP-SMX) 12
hourly with a total intended treatment duration of 20weeks. On his
review a month later, the patient was well with good glycemic
control. A repeated chest radiograph (Fig. 2) showed resolution of
the previous right-sided pleural effusion. He was discharged well
from the respiratory outpatient clinic upon completion of histreatment.2. Discussion
Melioidosis is endemic in Malaysia, Thailand, Singapore and
Australia. A study conducted in the state of Pahang in Peninsula
Malaysia demonstrated the incidence of this infection is approxi-
mately 6.1 per 100, 000 populations per year [4]. The lung is the
most commonly affected organ in melioidosis infection. Patients
can present with cough, fever or both as a result of pneumonia or a
primary lung abscess [3]. A spectrum of pulmonary inﬁltrations is
commonly seen; ranging from patchy to diffuse, lobar to multi-
lobar involvement. Pulmonary melioidosis manifesting as isolated
pleural effusion occurred in 12.2% of the total 162 cases reported
between 1996 and 2002 in study conducted in Thailand [2]. How-
ever on the Malaysian front, How et al. mentioned that the inci-
dence of Melioidosis reported in the state of Pahang in Peninsula
Malaysia exceeded that of Thailand but unfortunately the data on
the incidence of cases presented with isolated pleural effusion was
lacking [4].
Melioidosis can present either acute, or runs a sub-acute course.
It canmimic other diseases andmay cause unnecessary delay in the
initiation of appropriate antibiotics. Therefore, clinicians ought to
be vigilant to consider less common etiologies of pneumonia or
parapneumonic effusion if response to guideline-driven conven-
tional intravenous antibiotics shows poor response. In this case,
base on the history, clinical symptoms, pleural ﬂuid analysis and
chest radiograph ﬁndings the patient was initially treated for
partially treated community-acquired pneumonia complicated
with right sided parapneumonic effusion. His condition did not
improve despite escalating antibiotics treatment. Clinical
improvement was only observed after initiation of parenteral cef-
tazidime following successful isolation of B. pseudomallei.
A diagnosis of melioidosis requires isolation of B. pseudomallei
from various clinical specimens. This can either be blood, tissue
samples or aspirate cultures obtained from abscesses. B. pseudo-
mallei is a motile (with polar ﬂagella), aerobic gram-negative ba-
cillus and grows readily on routine culture media. Often enough, it
shows bipolar staining and is oxidase positive. Colonies of B.
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culture media and the type of strain isolated. They often become
wrinkled in appearance after incubation for 2e3 days [5]. Alter-
native methods of detecting B. pseudomallei are using polyclonal
(Pab-IFA) or monoclonal antibody (Mab-IFA). These tests can pro-
vide results as early as 24e48 h compare to blood culture. The
positive predictive values for Mab-IFA and Pab-IFA are 93.9% and
72.5% respectively [6].
Important risk factors for Melioidosis are such as diabetes, renal
disease, liver cirrhosis, thalassemia, alcoholism, use of immuno-
suppressive agents, cystic ﬁbrosis and kava (a Hawaiian drink)
consumption [7]. The antibiotic of choice is parenteral ceftazidime
or a carbapenem drug (either meropenem or imipenem). It should
be continued for a duration of at least 10 days follow by oral therapy
with trimethoprim-sulfamethoxazole (TMP-SMX) monotherapy or
combinationwith doxycycline for at least 12e20 weeks duration in
the eradication phase with a lower risk of relapse in the later [8]. In
contrast, guidelines from the northern territory of Australia sug-
gested intensive phase with parenteral antibiotics should be given
for at least 14 days duration. In the presence of severe infection,
duration of treatment can be extended up to 4 weeks duration or
parenteral carbapenem can be administered as an alternative drug
of choice [9]. Eradication phase should be continued for a minimal
period of three months duration [9].
Doxycycline has been used in combination with TMP-SMX for
eradication therapy in some parts of theworld. However, TMP-SMX
appears to be the crucial component of this combination regimen.
This was supported by the results of a multi-center, double-blind,
randomized controlled trial conducted in Thailand, where there
was no difference in the recurrent rates of culture-conﬁrmed
melioidosis in patients treated with either regime [8]. In this case,
the patient was discharged with a combination therapy of oral
TMP-SMX and doxycycline for a total duration of 20 weeks ac-
cording to local treatment protocol [10]. He achieved full recovery
on subsequent outpatient review.
3. Conclusion
In conclusion, melioidosis is known to cause pulmonary infec-
tion and isolated pleural effusion can be the only manifestation. In
countries where melioidosis is endemic, a high index of suspicion
should be considered in all high-risk individuals, who showed poor
response to initial parenteral antibiotics. Prompt microbiology re-
sults are undeniably important as well to guide early commence-
ment of appropriate antibiotic therapy as stereotypically driven
empirical antibiotic used is ineffective in treating Melioidosis and
can inﬂuence the outcome and recovery of the patient.
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